Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies
{{output}}
Acalabrutinib is a frontline agent for chronic lymphocytic leukemia (CLL). The objective of this experiment was to screen 21 cardiovascular drugs with a focus on elucidating the metabolic inhibition of acalabrutinib by finerenone in vitro and in vivo. The ultr... ...
